Medtronic. Dexcom. Abbott. Sanofi. Google. A lot of very large, well-known companies are investing heavily into innovating the diabetes space, and that innovation is exciting. But a disproportionate amount of the innovation around insulin delivery focuses on the insulin pump, a delivery device that’s only used by a small percentage of insulin users. Most insulin users — between 70 and 93 percent...
Patients Pending, a London-based health startup founded by one of the co-creators of Skype and his brother, has announced that it will follow up its Timesulin insulin pen cap with a Bluetooth-connected insulin pen cap, which the company hopes will help create smart dosing systems for patients with Type 1 diabetes who don’t use an insulin pump.
“Our hypothesis has been, so much of the investment...
